Press Release: Novartis: World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime

Novartis International AG / World's largest Alzheimer's survey reveals

most adults believe a cure will be developed in their lifetime.

Processed and transmitted by Nasdaq Corporate Solutions. The issuer is

solely responsible for the content of this announcement.

-- From a sample of over 10,000 adults, 62% are worried that they may

develop Alzheimer's disease and 91% believe the solution to tackling

diseases lies in medical research[1]

-- 79% are willing to take part in medical research but three-quarters (75%)

have no idea how to get involved[1]

-- This World Alzheimer's Month, in association with Alzheimer's Disease

International, Novartis, Amgen and Banner Alzheimer's Institute are

raising awareness about how to get involved in Alzheimer's research

The digital press release with multimedia content can be accessed here:

https://novartis.gcs-web.com/Worlds-largest-Alzheimer-survey-reveals-most-adults-believe-a-cure-will-be-developed-in-their-lifetime

Basel, September 17, 2018

-

Novartis, Amgen and Banner Alzheimer's Institute (BAI), in association

with Alzheimer's Disease International (ADI), today announced results

from the largest global survey to date investigating perceptions of

Alzheimer's disease. Findings show that most adults (62%) are worried

that they may develop Alzheimer's, while nearly the same proportion

believe it is likely a cure will be developed in their lifetime

(60%).[1] This World Alzheimer's Month, Novartis, Amgen, BAI and ADI are

raising awareness about how volunteers can take part in clinical studies

to benefit Alzheimer's research, potentially themselves and future

generations.

Alzheimer's is the leading cause of dementia, a disease affecting 50

million people worldwide and this number is expected to triple by

2050.[2] The survey of more than 10,000 people across 10 countries

revealed that 91% believe the solution to tackling diseases lies in

medical research and 79% are willing to participate.[1] However,

three-quarters (75%) have no idea how to get involved in medical

research.[1] In addition, 78% of adults are willing to get genetically

tested to identify their potential risk of developing Alzheimer's.[1]

(") At present, there is no cure and limited treatment options for

Alzheimer's, but this survey clearly shows that people are willing to

participate in research to help treat and to hopefully find a cure,"

said Paola Barbarino, Chief Executive Officer at ADI. "We need to

demystify and remove awareness barriers to participation in medical

research, making all suitable candidates aware of how they can get

involved."

Worldwide, more than 400 clinical studies are recruiting in

Alzheimer's.[3] However, slow enrollment is a costly and common obstacle

that undermines medical research.[4] There is a need for more people to

volunteer to advance scientific discovery.

"The results from this survey clearly demonstrate the need to raise

awareness about clinical studies globally," said Pierre N. Tariot, MD,

director of BAI and co-director of the Alzheimer's Prevention Initiative

(API). "Aside from funding, the greatest challenge in finding a way to

treat, slow, or prevent Alzheimer's is the recruitment and retention of

study participants. Scientists are making great progress in the fight

against this disease, but an estimated 80% of studies fail to meet

recruitment goals on time, which delays critically important research."

September 2018 marks the 7(th) World Alzheimer's Month and represents a

chance for people to raise awareness, fundraise and find out more about

how they can participate in research. In addition to the global survey

results, ADI will also launch their World Alzheimer Report 2018 entitled

The state of the art of dementia research: new frontiers, which looks at

the hopes and aspirations, the barriers and enablers to improving

dementia research globally. More information on the report can be found

here www.alz.co.uk/worldreport2018.

"Novartis thanks all the participants who took part in this important

survey. We have served patients in Neuroscience for over 70 years and

believe that a focus on prevention is vital to safeguard future

generations," said John Tsai, M.D., Global Head Drug Development and

Chief Medical Officer for Novartis. "This survey highlights that greater

awareness and support is needed. This is to ensure people have

sufficient knowledge about clinical research studies to make a

well-informed choice about getting involved, so that together we can

reimagine Alzheimer's care for the future."

Novartis, Amgen and BAI are sponsors of the API's Generation Program,

which is evaluating investigational treatments to help prevent or delay

the onset of Alzheimer's. The Program is enrolling volunteers aged 60-75

who are at higher risk of developing Alzheimer's but do not currently

have or show signs of the disease. Information can be found at

www.generationprogram.com. Learning about increased genetic risk as part

of a clinical study can result in a unique emotional response; pre- and

post-test genetic counselling is often recommended to help manage these

responses and provide information on implications for the individual and

their family.[5]

Information about clinical trials is widely available online and from

local patient advocacy groups. Details of Alzheimer's clinical studies

can be found on the ADI website www.alz.co.uk/clinical-trials/find and

the Alzheimer's Prevention Registry www.endALZnow.org/. Studies can also

be found within the ClinicalTrials.gov study database,

https://clinicaltrials.gov, under the search criteria 'Recruiting' and

'Alzheimer Disease'.

About the survey

The survey was conducted online by The Harris Poll on behalf of Novartis,

Amgen and Banner Alzheimer's Institute, among 10,095 adults 18+ living

in Argentina, Canada, China, France, Germany, Italy, Japan, Spain, the

UK and the US. The survey was conducted between July 25 and August 21,

2018. Figures for age by gender, income, education, race/ethnicity

(Canada and US only), region, size of household, marital status, and

employment status were weighted where necessary to bring them into line

with their actual proportions in the population.

The Alzheimer's Prevention Initiative (API) is an international

collaborative research effort formed to launch a new era of Alzheimer's

prevention research. Led by Banner Alzheimer's Institute, the API

conducts prevention trials in cognitively healthy people at increased

genetic risk for Alzheimer's disease. It will continue to establish the

brain imaging; biological and cognitive measurements needed to rapidly

test promising prevention therapies and provide registries to support

enrollment in future prevention trials. API is intended to provide the

scientific means, accelerated approval pathway with the cooperation of

the regulatory agencies and enrollment resources needed to evaluate the

range of promising Alzheimer's prevention therapies and find ones that

work. For more information, go to www.alzheimerspreventioninitiative.com

About Amgen and Novartis Neuroscience Collaboration

In August 2015, Novartis entered into a global collaboration with Amgen

to develop and commercialize pioneering treatments in the field of

migraine and Alzheimer's disease.

Disclaimer

This press release contains forward-looking statements within the

meaning of the United States Private Securities Litigation Reform Act of

1995. Forward-looking statements can generally be identified by words

such as "potential", "can", "will", "plan", "expect", "anticipate",

"look forward", "believe", "committed", "investigational", "pipeline",

"launch", "pioneering", or similar terms, or by express or implied

discussions regarding potential marketing approvals, new indications or

labeling for the investigational or approved products described in this

press release, or regarding potential future revenues from such

products. You should not place undue reliance on these statements. Such

forward-looking statements are based on our current beliefs and

expectations regarding future events and are subject to significant

known and unknown risks and uncertainties. Should one or more of these

risks or uncertainties materialize, or should underlying assumptions

prove incorrect, actual results may vary materially from those set forth

in the forward-looking statements. There can be no guarantee that the

investigational or approved products described in this press release

will be submitted or approved for sale or for any additional indications

or labelling in any market, or at any particular time. Nor can there be

any guarantee that such products will be commercially successful in the

future. In particular, our expectations regarding such products could be

affected by, among other things, the uncertainties inherent in research

and development, including clinical trial results and additional

analysis of existing clinical data; regulatory actions or delays or

government regulation generally; global trends toward health care cost

containment, including government, payor and general public pricing and

reimbursement pressures; our ability to obtain or maintain proprietary

intellectual property protection; the particular prescribing preferences

of physicians and patients; general political and economic conditions;

safety, quality or manufacturing issues; potential or actual data

security and data privacy breaches, or disruptions of our information

technology systems, and other risks and factors referred to in Novartis

AG's current Form 20-F on file with the US Securities and Exchange

Commission. Novartis is providing the information in this press release

as of this date and does not undertake any obligation to update any

forward-looking statements contained in this press release as a result

of new information, future events or otherwise.

About Novartis

(MORE TO FOLLOW) Dow Jones Newswires

September 17, 2018 16:30 ET (20:30 GMT)